- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06277037
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
March 29, 2024 updated by: Arbutus Biopharma Corporation
A Long-Term Follow-up Study for Subjects With Chronic Hepatitis B Previously Treated With Imdusiran (AB-729)
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy.
Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study [EOS] visit) from their imdusiran clinical trial (the "parent study").
No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted.
Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
35
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael Child
- Phone Number: 267-332-6213
- Email: mchild@arbutusbio.com
Study Locations
-
-
-
Murdoch, Australia, 6150
- Fiona Stanley Hospital
-
Contact:
- Sam Galhenage
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
Contact:
- Stuart Roberts
-
Contact:
- Email: S.Roberts@alfred.org.au
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Shatin, Hong Kong
- Prince of Wales Hospital
-
Contact:
- Grace Wong
-
-
-
-
-
Changhua city, Taiwan, 600566
- Changhua Christian Hospital
-
Chiayi City, Taiwan, 60002
- Chia-Yi Christian Hospital
-
Contact:
- Chi-Yi Chen
-
Kaohsiung, Taiwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Contact:
- Wan-Long Chuang
-
Kaohsiung, Taiwan, 82445
- E-DA Hospital
-
Contact:
- Gin-Ho Lo
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Contact:
- Sheng-Shun Yang
-
Taoyuan, Taiwan, 33305
- Chang Gung Medical Foundation Linkou
-
Contact:
- Chao-Wei Hsu
-
-
-
-
-
Cardiff, United Kingdom, CF144XW
- University Hospital of Wales, Cardiff
-
Contact:
- Jonathan Underwood
-
London, United Kingdom, SE59RS
- King's College Hospital
-
Contact:
- Kosh Agarwal
-
London, United Kingdom, E11FR
- Royal London Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
CHB subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy at the end of study visit.
Description
Key Inclusion Criteria:
- Have participated in a prior imdusiran clinical trial,
- Have discontinued NA therapy in that trial and remain off NA therapy,
- Have completed less than 3 years of follow-up visits after NA discontinuation in the parent study.
- Have the ability to review and provide signed informed consent which includes compliance with all protocol-specified visit schedules and requirements.
Exclusion Criteria:
- Not applicable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the durability of effect of imdusiran on HBV parameters
Time Frame: Up to 96 weeks
|
Change from pre-"parent" study baseline and over time in HBsAg, HBV DNA, and hepatitis B surface antibody (HBsAb) at each timepoint.
|
Up to 96 weeks
|
To evaluate the durability of effect of imdusiran on HBV parameters
Time Frame: Up to 96 weeks
|
Proportion of subjects who remain off NA therapy and duration off NA therapy, if applicable
|
Up to 96 weeks
|
To evaluate the durability of effect of imdusiran on HBV parameters
Time Frame: Up to 96 weeks
|
Proportion of subjects who restart NA therapy, if applicable
|
Up to 96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 15, 2024
Primary Completion (Estimated)
August 30, 2029
Study Completion (Estimated)
October 30, 2029
Study Registration Dates
First Submitted
February 14, 2024
First Submitted That Met QC Criteria
February 22, 2024
First Posted (Actual)
February 26, 2024
Study Record Updates
Last Update Posted (Actual)
April 1, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- AB-729-204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Long Term Follow-up
-
Sorrento Therapeutics, Inc.Enrolling by invitationLong-term Follow-upUnited States
-
Spinal KineticsEnrolling by invitation
-
University Hospital, LilleMinistry of Health, FranceRecruitingBariatric Surgery | Weight Regain | Long Term Follow-UpFrance
-
Ruhr University of BochumNot yet recruitingOne Week Follow-up Assessment | Six Weeks Follow-up Assessment | Three Months Follow-up AssessmentGermany
-
Oyster Point Pharma, Inc.CompletedLong Term Follow up Dry Eye DiseaseUnited States
-
Alaa Gameil Abd El-salam HussienAssiut UniversityActive, not recruitingThe Aim of This Study is to Follow up Short Term "3-6 Months"& Mid Term" 6-12months "Outcomes of Vascular Access" Native and Synthetic "in ESRD PediatricsEgypt
-
University of PennsylvaniaCompleted
-
University Hospital, AntwerpRecruitingEducation | Mobile Health | Follow-upBelgium
-
Planned Parenthood League of MassachusettsSociety of Family PlanningCompletedFollow-up After Uterine EvacuationUnited States
-
Vanderbilt University Medical CenterCompleted
Clinical Trials on Non-interventional
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Papworth Hospital NHS Foundation TrustInnovate UK; Cystic Fibrosis Trust; US Cystic Fibrosis FoundationRecruitingCystic FibrosisUnited Kingdom
-
Royal Marsden NHS Foundation TrustRecruiting
-
Regeneron PharmaceuticalsRecruitingHemophilia BUnited States, Germany, United Kingdom, Canada
-
Henri Mondor University HospitalEuropean Society of Intensive Care MedicineRecruitingFournier Gangrene | Necrotizing Soft Tissue Infection | Necrotizing FasciitisFrance
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Respiratory Effectiveness GroupBoehringer IngelheimCompletedChronic Obstructive Pulmonary DiseaseKorea, Republic of, Singapore, Malta, Italy, Slovenia, Spain
-
Eurasian Association of TherapistsCompletedCardiovascular Diseases | Pneumonia | Hypertension | Diabetes | Covid19 | Coronary Heart Disease | Copd | CKD | Overweight and Obesity | SARS-CoV-2 Infection | Cardiac EventRussian Federation